MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.89
-0.70 (-2.37%)
As of 1:50PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close29.59
Open29.26
Bid28.97 x 900
Ask28.98 x 1000
Day's Range28.35 - 29.25
52 Week Range26.03 - 47.82
Volume3,227,336
Avg. Volume5,010,283
Market Cap14.897B
Beta (3Y Monthly)1.57
PE Ratio (TTM)27.57
EPS (TTM)1.05
Earnings DateFeb 26, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est42.63
Trade prices are not sourced from all markets
  • The Zacks Analyst Blog Highlights: Mylan, Altice USA and Keysight Technologies
    Zacks8 hours ago

    The Zacks Analyst Blog Highlights: Mylan, Altice USA and Keysight Technologies

    The Zacks Analyst Blog Highlights: Mylan, Altice USA and Keysight Technologies

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    # Mylan NV ### NASDAQ/NGS:MYL View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $4.72 billion over the last one-month into ETFs that hold MYL are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Can Stanley Black & Decker’s Q4 Earnings Beat the Estimates?
    Market Realist4 days ago

    Can Stanley Black & Decker’s Q4 Earnings Beat the Estimates?

    Stanley Black & Decker: What to Expect from Its Q4 Earnings(Continued from Prior Part)Stanley Black & Decker’s Q4 EPS estimates Stanley Black & Decker (SWK) is expected to post an adjusted EPS of $2.1 in the fourth quarter—a decrease

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    # Mylan NV ### NASDAQ/NGS:MYL View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $6.67 billion over the last one-month into ETFs that hold MYL are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MarketWatch6 days ago

    Adamis stock surges on release of EpiPen alternative

    Adamis Pharmaceuticals Corp. shares surged in the extended session Wednesday after the biotech company said its partner Sandoz Inc. launched an alternative to epinephrine auto-injectors like Mylan NV's EpiPen. Adamis shares rallied 14% after hours, after closing up 4.8% at $2.63 in regular trading Wednesday. Adamis said that Sandoz, which is part of Novartis AG , launched Symjepi, a single-dose treatment for allergic reactions including anaphylaxis. "With recent news of epinephrine product shortages in the U.S., we worked together with Sandoz in getting this potentially life-saving quality product into the market as quickly as possible," said Dennis Carlo, chief executive at Adamis, in a statement.

  • Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
    Zacks6 days ago

    Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

    Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C

  • European nations weigh impact of Brexit on drug supplies
    Reuters7 days ago

    European nations weigh impact of Brexit on drug supplies

    FRANKFURT/DUBLIN (Reuters) - Germany's drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs, while Ireland has drawn up a list of 24 medicines whose supply would be most vulnerable if Britain fails to conclude a divorce deal. Irish Prime Minister Leo Varadkar said a working group of health officials meeting weekly for the last two years had drawn up the watch list, but advised against stockpiling. "It is a really important message that I want to deliver to people in Ireland today, both to patients and pharmacists, that there is no need to stockpile medicines," Health Minister Simon Harris said at a news conference, warning that such action could inadvertently disturb the supply chain.

  • Reuters7 days ago

    European nations weigh impact of Brexit on drug supplies

    FRANKFURT/DUBLIN, Jan 15 (Reuters) - Germany's drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs, while Ireland has drawn up a list of 24 medicines whose supply would be most vulnerable if Britain fails to conclude a divorce deal. Irish Prime Minister Leo Varadkar said a working group of health officials meeting weekly for the last two years had drawn up the watch list, but advised against stockpiling. "It is a really important message that I want to deliver to people in Ireland today, both to patients and pharmacists, that there is no need to stockpile medicines," Health Minister Simon Harris said at a news conference, warning that such action could inadvertently disturb the supply chain.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    # Mylan NV ### NASDAQ/NGS:MYL View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $10.83 billion over the last one-month into ETFs that hold MYL are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
    Zacks12 days ago

    Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

    Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

  • INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
    Zacks12 days ago

    INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

    INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.

  • Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?
    Market Realist12 days ago

    Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?

    Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## Debt changes in 2018 In the first nine months of 2018, Teva Pharmaceutical (TEVA) reduced its net debt level by $3.9 billion to $27.6 billion. According to the company’s third-quarter earnings conference call, it deployed the proceeds it received from its issuance of new corporate bonds to repay its term loans as well as part of its bonds. The company has also been focusing on using its cash flows to reduce its net debt levels. At the end of September 2018, the company had gross debt of below $30 billion and cash worth $1.9 billion. At the end of September 2018, Mylan (MYL) had a net debt-to-adjusted EBITDA ratio of 3.8x. According to Mylan’s third-quarter earnings conference call, the company is targeting the repayment of $1.2 billion worth of debt by the end of 2019. ## Debt projections Analysts expect Teva Pharmaceutical’s net debt to be $28.37 billion, $25.06 billion, and $22.47 billion, respectively, at the end of 2018, 2019, and 2020. The company is expected to reduce its net debt levels by 9.97%, 11.66%, and 10.33% YoY (year-over-year), respectively, in 2018, 2019, and 2020. Analysts expect Mylan’s net debt to be $12.36 billion, $10.66 billion, and $8.27 billion, respectively, at the end of 2018, 2019, and 2020. The company is expected to reduce its net debt levels by 14.34%, 13.78%, and 22.36% YoY, respectively, in 2018, 2019, and 2020. Analysts expect Teva Pharmaceutical’s net debt-to-adjusted EBITDA ratios to be 5.26x, 4.76x, and 4.14x, respectively, in 2018, 2019, and 2020. They expect Mylan’s net debt-to-adjusted EBITDA ratios to be 3.28x, 2.66x, and 1.95x, respectively, in 2018, 2019, and 2020. Compared to Teva Pharmaceutical, Mylan not only has a lower absolute level of net debt but is also expected to reduce its debt levels at a much faster pace from 2018 to 2020. Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory?

  • Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
    Zacks12 days ago

    Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect

    Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.

  • MYL vs. SUPN: Which Stock Is the Better Value Option?
    Zacks12 days ago

    MYL vs. SUPN: Which Stock Is the Better Value Option?

    MYL vs. SUPN: Which Stock Is the Better Value Option?

  • Teva Pharmaceutical or Mylan: Which Is More Cost Optimal?
    Market Realist12 days ago

    Teva Pharmaceutical or Mylan: Which Is More Cost Optimal?

    Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## Expense strategy According to Teva Pharmaceutical’s (TEVA) 37th Annual J.P. Morgan Healthcare Conference transcript, the company reduced its spending base by $1.8 billion in the first nine months of 2018. The company expects to achieve its restructuring program target of a $3.0 billion reduction in its spending base in 2019. Mylan (MYL) is also focusing on cost optimization by working on integrating its various businesses across the world as well as its acquired businesses to form One Mylan. ## Expense projections Wall Street analysts expect Teva Pharmaceutical’s SG&A (selling, general, and administrative) expenses as a percentage of its revenues to be 20.99%, 19.65%, and 19.25%, respectively, in 2018, 2019, and 2020. On the other hand, Mylan is expected to report SG&A expenses as a percentage of its revenues of 19.49%, 19.26%, and 18.76%, respectively, in 2018, 2019, and 2020. Both companies are expected to reduce their SG&A-to-revenue percentages from 2018 to 2020. However, Mylan is expected to spend a lower percentage of its revenue on marketing and commercial activities than Teva. Analysts expect Teva Pharmaceutical’s R&D (research and development) expenses as a percentage of its revenues to be 5.75%, 5.52%, and 5.42%, respectively, in 2018, 2019, and 2020. On the other hand, Mylan is expected to report R&D expenses as a percentage of its revenues of 5.37%, 5.53%, and 5.31%, respectively, in 2018, 2019, and 2020. Both companies are expected to dedicate a similar percentage of their revenues to R&D activities from 2018 to 2020. In the next article, we’ll compare the shareholder value generated by Teva Pharmaceutical and Mylan in greater detail.   Continue to Next Part Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory?

  • Teva Pharmaceutical or Mylan: Which Company Has Higher Margins?
    Market Realist12 days ago

    Teva Pharmaceutical or Mylan: Which Company Has Higher Margins?

    Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## Long-term targets According to Teva Pharmaceutical’s (TEVA) J.P. Morgan Healthcare Conference investor presentation, it has an operating margin target of 30%, a cash-to-earnings percentage target of more than 80%, and a net debt-to-EBITDA target of below 3x for the next three to five years. The company also plans to achieve a net debt-to-EBITDA ratio of below 4x by the end of 2020. According to the company’s presentation transcript, it plans to create shareholder value by focusing on reducing its debt levels rather than raising additional equity. It also plans to focus on the ongoing launch of Ajovy and Austedo to drive its future revenue growth. The increased adoption of these products could help partially offset the impact of the challenges arising from its loss of exclusivities for Copaxone, bendamustine, and ProAir HFA. Mylan (MYL) also has a well-diversified portfolio across a variety of product categories and geographies. In its third-quarter earnings investor presentation, Mylan said that it expected its North American revenue to fall in the mid-teens in terms of percentage. Its Europe and the Rest of World revenues are expected to rise in the high single digits year-over-year. ## Margin projections Wall Street analysts expect Teva Pharmaceutical’s gross margins to be 50.75%, 50.87%, and 51.10%, respectively, in 2018, 2019, and 2020. On the other hand, analysts expect Mylan to report gross margins of 54.12%, 54.61%, and 54.71%, respectively, in 2018, 2019, and 2020. Analysts also expect Teva Pharmaceutical’s adjusted net income margins to be 16.04%, 17.14%, and 18.13%, respectively, in 2018, 2019, and 2020. They expect Mylan to report adjusted net income margins of 21.09%, 22.03%, and 22.92%, respectively, in 2018, 2019, and 2020. Mylan is thus expected to report higher profit margins than Teva Pharmaceutical from 2018 to 2020. In the next article, we’ll compare the cost structures of Teva Pharmaceutical and Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory?

  • Teva or Mylan: Whose Earnings Are Growing Faster?
    Market Realist13 days ago

    Teva or Mylan: Whose Earnings Are Growing Faster?

    Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## Earnings guidance In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) forecast 2018 non-GAAP (generally accepted accounting principles) EPS of $2.80–$2.95, a significant increase at the midpoint from the guidance of $2.55–$2.80 it had provided in August 2018 and the guidance of $2.25–$2.50 it had provided in February 2018. In its third-quarter earnings investor presentation, Teva Pharmaceutical forecast 2018 non-GAAP EBITDA of $5.2 billion–$5.4 billion, a significant increase at the midpoint from the guidance of $5.0 billion–$5.3 billion it had provided in August 2018 and the guidance of $4.7 billion–$5.0 billion it had provided in February 2018. In its third-quarter earnings investor presentation, Teva Pharmaceutical forecast 2018 non-GAAP operating income of $4.6 billion–$4.8 billion, a significant increase at the midpoint from the guidance of $4.3 billion–$4.6 billion it had provided in August 2018 and the guidance of $4.0 billion–$4.3 billion it had provided in February 2018. In its third-quarter earnings investor presentation, Mylan (MYL) forecast adjusted 2018 EPS of $4.55–$4.90. ## Wall Street estimates Wall Street analysts expect Teva Pharmaceutical’s non-GAAP EPS to be $2.93, $2.83, and $2.95, respectively, in 2018, 2019, and 2020, implying YoY changes of -26.88%, -3.51%, and 4.43%, respectively. On the other hand, Wall Street analysts expect Mylan’s non-GAAP EPS to be $4.68, $5.11, and $5.49, respectively, in 2018, 2019, and 2020, implying YoY growth rates of 2.63%, 9.16%, and 7.52%, respectively. Compared to Teva Pharmaceutical, Mylan is expected to report higher non-GAAP EPS in absolute terms in all years from 2018 to 2020. Additionally, unlike Teva Pharmaceutical, Mylan is expected to report a gradual rise in its non-GAAP EPS from 2018 to 2020. In the next article, we’ll compare the margins of Teva Pharmaceutical and Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory?

  • Teva or Mylan: Who Has the More Promising Revenue Trajectory?
    Market Realist13 days ago

    Teva or Mylan: Who Has the More Promising Revenue Trajectory?

    Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## Revenue guidance In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) forecast total 2018 revenue in the range of $18.6 billion–$19.0 billion. This guidance was a slight change from the guidance of $18.5 billion–$19.0 billion it had provided in August 2018 and the guidance of $18.3 billion–$18.8 billion it had provided in February 2018. According to the investor presentation, the company also expects its North American business, which includes its US Generics, US Speciality, Canada, and Anda businesses, to report revenue of $9.0 billion in 2018. According to the company’s third-quarter conference call, it expects its generic business revenue to stabilize in future quarters due to its strategy of continuing only with profitable business lines and exiting loss-making product categories. In its third-quarter earnings investor presentation, Mylan (MYL) forecast total 2018 revenue in the range of $11.25 billion–$12.25 billion, almost flat YoY (year-over-year). ## Wall Street estimates Wall Street analysts expect Teva Pharmaceutical’s revenues to be $18.85 billion, $17.94 billion, and $17.83 billion, respectively, in 2018, 2019, and 2020, implying YoY revenue falls of 15.81%, 4.82%, and 0.58%, respectively. On the other hand, analysts expect Mylan’s revenues to be $11.49 billion, $11.99 billion, and $12.36 billion, respectively, in 2018, 2019, and 2020, implying YoY revenue rises of -3.55%, 4.18%, and 3.30%, respectively. Teva Pharmaceutical is expected to report a falling revenue trajectory, while Mylan is expected to report a modest rise in revenue from 2018 to 2020. In the next article, we’ll compare the earnings growth prospects of Teva Pharmaceutical and Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 4 - Teva or Mylan: Whose Earnings Are Growing Faster?

  • What Are Analysts Recommending for Mylan in January?
    Market Realist13 days ago

    What Are Analysts Recommending for Mylan in January?

    Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## MYL’s price movements On January 8, Mylan (MYL) closed at $29.87, up 0.40% from its previous closing price. The company closed at a premium of 14.73% to its 52-week low price of $26.03 and at a discount of 37.54% to its 52-week high price of $47.82. As of January 8, Mylan’s market cap is $15.37 billion. The company is trading at a trailing PE ratio of 24.13x and a forward PE ratio of 5.85x. Based on its closing price on January 8, the company had reported returns of 9.01% in the last week, -6.19% in the last month, and -15.36% in the last quarter. It had also reported returns of -19.51% in the last half year, -32.94% in the last year, and 9.01% YTD (year-to-date). Based on its closing price on January 7, the US healthcare sector represented by the Vanguard Health Care ETF (VHT) had reported returns of 1.47% in the last week, -6.03% in the last month, and -8.31% in the last quarter. VHT had also reported returns of -1.45% in the last half year, 2.56% in the last year, and 1.47% YTD. ## Analysts’ recommendations and target prices for Mylan The 12-month consensus analyst recommendation for Mylan as of January 9 is a “buy.” The 12-month consensus target price for the company is $42.63, 42.72% higher than its closing price on January 8. The highest target price estimate for the company is $55, and the lowest target price estimate is $28. Of the 17 analysts covering Mylan on January 9, seven analysts have rated the company as a “strong buy,” six have rated it as a “buy,” and four have rated it as a “hold.” In the next article, we’ll compare the revenue growth prospects of Teva Pharmaceutical and Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory? * Part 4 - Teva or Mylan: Whose Earnings Are Growing Faster?

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    # Mylan NV ### NASDAQ/NGS:MYL View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding MYL are favorable, with net inflows of $19.66 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Mylan (MYL) a Great Value Stock Right Now?
    Zacks14 days ago

    Is Mylan (MYL) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • 4 Oversold Stocks Ready to Rise
    Investopedia14 days ago

    4 Oversold Stocks Ready to Rise

    While the stock market’s plunge in recent months has lowered valuations of more than 20% of S&P 500 companies to a price to earnings ratio below 10, only a fraction of those look like real bargains.

  • Barrons.com18 days ago

    Four Low P/E Stocks That Look Like Good Bets

    The stock market’s scratch-and-dent bin is brimming with new entrants. This past week, 103 companies in the S&P 500 index were trading at price/earnings ratios below 10. Some companies, like (GM) (ticker: GM), trading at 5.6 times next-four-quarter earnings estimates, are longtime members of the single-digit P/E club.

  • Should You Be Concerned About Mylan N.V.’s (NASDAQ:MYL) ROE?
    Simply Wall St.18 days ago

    Should You Be Concerned About Mylan N.V.’s (NASDAQ:MYL) ROE?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • Ironwood/Allergan Settle Linzess Patent Litigation With Mylan
    Zacks19 days ago

    Ironwood/Allergan Settle Linzess Patent Litigation With Mylan

    Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.